Apimeds Pharmaceuticals US, Inc. (APUS) Q1 2026 Annual Earnings
APUS·Reported May 4, 2026·Before market open
Diluted EPS came in at $-0.08 (-60.0% YoY).
Diluted EPS
$-0.08
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Apimeds Pharmaceuticals US, Inc.'s Q1 2026 earnings report.
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q1 2026 earnings on May 4, 2026 before market open.
Apimeds Pharmaceuticals US, Inc. reported diluted EPS of $-0.08 for Q1 2026.
Compared to the same quarter a year prior, diluted EPS declined 60.0% from $-0.05.
You can read the 8-K earnings release (0001213900-26-051125) and the 10-K periodic report (0001213900-26-051139) directly on SEC EDGAR. The filing index links above go to sec.gov.